Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.
Synexus is set to take part in a number of global ophthalmology trials following recent investment in clinical research expertise and technology in this area.
Synexus' Michael Fort has been named CEO of the Year at the finals of the British Venture Capital Association's (BVCA) Portfolio Company Management Awards.
Michael, who joined Synexus in 2001 as Commercial Director became CEO in 2006 and has been the driving force behind the company's rapid expansion to become the largest multinational company dedicated to the recruitment and running of trials at its own research centres. The company now has a global presence with 26 Dedicated Research Centres, and is continuing with plans for continued growth in Asia.
Synexus has appointed Dr Glynis Neagle as Chief Medical Officer. Manchester-based Synexus has become the world's largest company specialising in the recruitment and running of clinical trials at its own Dedicated Research Centres. The company recently welcomed a new Chief Executive, Dr Christophe Berthoux and this latest appointment supports the company's strategy not only to continue its aggressive growth plans, but also to ensure it keeps medical practice at the heart of its expanding operations. Dr Neagle will be responsible for all of the company's medical, ethical and regulatory issues in addition to leading the group's knowledge base in its expansion into new disease and therapy areas worldwide.
Synexus, the world's leading organisation dedicated to the recruitment and running of clinical trials, is getting ready for a new phase of sustained growth. As part of this drive it has today announced changes to its executive management team with the appointment of Dr Christophe Berthoux as Chief Executive. His appointment will be effective from 12th September. Dr Berthoux was EVP Global Sales & Marketing and Chief Commercial Officer at Charles River, where he created a new global organisational structure across the company and was responsible for a number of strategic acquisitions. Michael Fort, the existing CEO, will become full-time Executive Deputy Chairman with responsibility for the continued development and expansion of the Group.
Synexus clinical trials activity in Hungary has increased by 25% during the first half of 2010. The company's Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company's most successful CEE sites. The Budapest-based operation has been involved in excess of 74 trials since being acquired by Synexus, and randomized over 600 patients.
Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials took over its first site in Kiev at the world renowned Centre for Radiation Medicine in January this year when it finalised its acquisition of ClinPharm.
Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials is expanding its operations in Gydnia, Poland when it moves to new premises later this year. It has also recently increased the capacity of its original centre in Wroclaw by several hundred square metres.
Michael Fort, Chief Executive of Synexus goes into the UK final of the Ernst & Young Entrepreneur of the Year Awards 2010 after being named North West and Midlands Turnaround Entrepreneur in this year’s competition.
Manchester-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, has recently invested in Doppler Ultrasound equipment for each of its seven UK-based Dedicated Research Centres. After training for all Synexus doctors, the facilities are now being used as part of the drive to recruit patients to a new diabetes study.
At the first Patient Recruitment in Clinical Trials Conference held in South Africa, Dr Sanet Aspinall, Managing Director of Synexus in South Africa, emphasised the importance of being part of a global network which means that it is increasingly likely to be included in international trials rather than purely local studies.
During the first quarter of 2010 Synexus has seen growth in Germany reach thirty per cent as international sponsors take advantage of the additional patient reach the company can now offer following its acquisition of eight sites there as part of its takeover of Leipzig-based Clinpharm at the end of 2009.
Following the recent announcement from Manchester-based Synexus that they had randomised 2,700 patients in just ten months for an osteoporosis study, the company has once again demonstrated that it is possible to recruit the agreed number of patients within the study deadline by recruiting 87% of patients to another study for the same therapeutic area.
Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials supports the recent call to include more elderly people in clinical trials. Synexus' Dedicated Recruitment Centres across the UK and overseas, have been successfully recruiting older people to their trials for some time now and are keen to see this trend continue.
It took clinical trial experts Synexus, just ten months to carry out 52,000 DEXA scans and randomise over 2,700 patients across twelve of their UK, European and African dedicated research centres.
Following her appointment in 2009 as Operations Manager for Hungary, Dr Erika Nemeth has been promoted to Country Manager as Synexus increases capacity in its Hungarian operations.
Synexus has appointed Jeremy Hickling as their Senior Vice President, Portfolio Management. With eleven year’s spent working in the pharmaceutical industry, the last five with PAREXEL, Jeremy brings significant, senior level experience to his new role. Synexus, based just outside Manchester has grown to become the world largest multinational organisation specialising in the recruitment of patients and the running of trials at its own dedicated research centres.
Following their recent announcement of the deal to acquire German company, ClinPharm, Manchester-based Synexus is celebrating the end of 2009 with the news that the acquisition has now been finalised. This increases the number of Synexus dedicated research centres to twenty-six.
Follow Synexus on Twitter
Back to top ^
